Physician

Vitor Hugo Abascal Pastorini Filho, M.D.

According to 2025 Medicare claims, Vitor Filho, M.D. (NPI: 1215165279) practices hematology/oncology in the Ocala, FL market, with the plurality of this provider's patient population coming from Marion, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34474-9673.

Filho's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,126 traditional Medicare patients, billed 207,593 HCPCS/CPT codes, and received $3,037,850 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,533 prescription claims across 269 beneficiaries totaling $3,465,129 in drug costs, led by Revlimid (Lenalidomide). 2020 DME data shows 174 claims. Open Payments data shows 181 records totaling $3,806. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $337,952 and ending at $3,037,850. Concurrently, Part D prescription costs have risen steadily, from $3,147 to $3,465,129. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	202	19,071	$337,952
2017	461	142,060	$1,918,622
2018	571	200,143	$2,015,316
2019	634	174,353	$2,558,151
2020	564	130,750	$2,390,998
2021	647	54,939	$993,705
2022	901	129,558	$1,534,902
2023	1,157	187,917	$2,840,873
2024	1,126	207,593	$3,037,850

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	22	$3,147
2016	34	138	$5,838
2017	97	739	$436,538
2018	132	846	$328,040
2019	165	988	$268,812
2020	141	843	$886,739
2021	114	420	$637,697
2022	169	762	$1,138,715
2023	231	984	$1,606,228
2024	269	1,533	$3,465,129

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	35	$6,557
2019	N/R	140	$9,087
2020	N/R	174	$11,139
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	298	787	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	321	493	$64
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	416	865	$13
36415	Insertion of needle into vein for collection of blood sample	787	1,986	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	742	1,921	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	51	1,309	$828,164
Venclexta	Venetoclax	30	888	$375,234
Erleada	Apalutamide	23	690	$293,011
Imbruvica	Ibrutinib	13	364	$213,145
Tagrisso	Osimertinib Mesylate	12	360	$179,457

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	181	$3,806	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Vitor Hugo Abascal Pastorini Filho, M.D.?

Tedicare shows public-source Medicare data for Vitor Hugo Abascal Pastorini Filho, M.D. (NPI 1215165279), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Vitor Hugo Abascal Pastorini Filho, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Vitor Hugo Abascal Pastorini Filho, M.D.?

Vitor Hugo Abascal Pastorini Filho, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Vitor Hugo Abascal Pastorini Filho, M.D. have Open Payments data?

Vitor Hugo Abascal Pastorini Filho, M.D. has 181 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.